Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 3:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Severe Eosinophilic Asthma Clear all

Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

NCT01508936

View directory record Official record

Conditions: Eosinophilic Asthma
Interventions: Reslizumab, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 66
States / cities: Birmingham, Alabama • Homewood, Alabama • Jasper, Alabama + 58 more

Source: ClinicalTrials.gov public record

Updated Jun 26, 2016 · Synced May 22, 2026, 3:53 AM EDT

Terminated Phase 3 Interventional

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)

NCT05813288

View directory record Official record

Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Interventions: Dexpramipexole Dihydrochloride, Placebo; Drug
Lead sponsor: Areteia Therapeutics; Industry
Eligibility: 12 Years to 99 Years

Enrollment: 654 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 76
States / cities: Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 64 more

Source: ClinicalTrials.gov public record

Updated Dec 14, 2025 · Synced May 22, 2026, 3:53 AM EDT

Recruiting Phase 3 Interventional

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)

NCT05692180

View directory record Official record

Conditions: Asthma
Interventions: Benralizumab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 18 Years

Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 28
States / cities: Mobile, Alabama • Montgomery, Alabama • Tucson, Arizona + 24 more

Source: ClinicalTrials.gov public record

Updated May 5, 2026 · Synced May 22, 2026, 3:53 AM EDT

Completed Phase 3 Interventional Results available

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04718389

View directory record Official record

Conditions: Asthma
Interventions: GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS); Biological · Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older

Enrollment: 1,717 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 119
States / cities: Birmingham, Alabama • Scottsboro, Alabama • Litchfield Park, Arizona + 94 more

Source: ClinicalTrials.gov public record

Updated May 17, 2026 · Synced May 22, 2026, 3:53 AM EDT

Completed Phase 2 Interventional Results available

GB001 in Adult Subjects With Moderate to Severe Asthma

NCT03683576

View directory record Official record

Conditions: Asthma
Interventions: GB001, Placebo; Drug
Lead sponsor: GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.; Industry
Eligibility: 18 Years to 74 Years

Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 47
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 41 more

Source: ClinicalTrials.gov public record

Updated Sep 15, 2021 · Synced May 22, 2026, 3:53 AM EDT

Completed Phase 3 Interventional Results available

A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04718103

View directory record Official record

Conditions: Asthma
Interventions: GSK3511294, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older

Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 41
States / cities: Alabaster, Alabama • Mobile, Alabama • Phoenix, Arizona + 34 more

Source: ClinicalTrials.gov public record

Updated Nov 28, 2024 · Synced May 22, 2026, 3:53 AM EDT

Completed Phase 2 Interventional Results available

Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children

NCT02377427

View directory record Official record

Conditions: Asthma
Interventions: Mepolizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Years to 11 Years

Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 4
States / cities: San Diego, California • Oklahoma City, Oklahoma • Medford, Oregon + 1 more

Source: ClinicalTrials.gov public record

Updated Dec 2, 2019 · Synced May 22, 2026, 3:53 AM EDT

Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

NCT01312961

View directory record Official record

Conditions: Asthma
Interventions: Dupilumab, Placebo (for Dupilumab), Fluticasone/Salmeterol combination therapy, Fluticasone monotherapy, Albuterol, Levalbuterol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 50
States / cities: Anaheim, California • Long Beach, California • Los Angeles, California + 42 more

Source: ClinicalTrials.gov public record

Updated Jun 7, 2017 · Synced May 22, 2026, 3:53 AM EDT

Completed Phase 3 Interventional Results available

PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma

NCT04305405

View directory record Official record

Conditions: Severe Uncontrolled Asthma
Interventions: Benralizumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 14 Years

Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: Los Angeles, California • Orlando, Florida • Lincoln, Nebraska + 4 more

Source: ClinicalTrials.gov public record

Updated May 17, 2023 · Synced May 22, 2026, 3:53 AM EDT

Recruiting Phase 2 Interventional

A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

NCT07323654

View directory record Official record

Conditions: Eosinophilic Asthma
Interventions: KT-621, Placebo; Drug · Other
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 20
States / cities: Long Beach, California • Northridge, California • Redding, California + 16 more

Source: ClinicalTrials.gov public record

Updated May 17, 2026 · Synced May 22, 2026, 3:53 AM EDT

Active, not recruiting Phase 4 Interventional

Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics

NCT03953300

View directory record Official record

Conditions: Asthma
Interventions: Benralizumab, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years

Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 16 more

Source: ClinicalTrials.gov public record

Updated May 4, 2026 · Synced May 22, 2026, 3:53 AM EDT

Completed No phase listed Observational

RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.

NCT05180357

View directory record Official record

Conditions: Severe Eosinophilic Asthma, Nasal Polyps
Interventions: FASENRA(benralizumab); Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years

Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Centennial, Colorado • Denver, Colorado • Glendale, New York + 5 more

Source: ClinicalTrials.gov public record

Updated Apr 18, 2023 · Synced May 22, 2026, 3:53 AM EDT

Completed Phase 3 Interventional Results available

A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation

NCT02869438

View directory record Official record

Conditions: Asthma
Interventions: Benralizumab, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 16
States / cities: Scottsboro, Alabama • Gilbert, Arizona • Denver, Colorado + 13 more

Source: ClinicalTrials.gov public record

Updated Oct 28, 2019 · Synced May 22, 2026, 3:53 AM EDT

Completed Phase 4 Interventional Results available

BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging

NCT05552508

View directory record Official record

Conditions: Asthma
Interventions: Benralizumab; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years

Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Walnut Creek, California • Loxahatchee Groves, Florida • Plantation, Florida + 7 more

Source: ClinicalTrials.gov public record

Updated Mar 24, 2025 · Synced May 22, 2026, 3:53 AM EDT

Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control

NCT02281318

View directory record Official record

Conditions: Asthma
Interventions: Mepolizumab, Placebo, SOC; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older

Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 24
States / cities: Birmingham, Alabama • Fresno, California • Long Beach, California + 20 more

Source: ClinicalTrials.gov public record

Updated Aug 5, 2018 · Synced May 22, 2026, 3:53 AM EDT

Completed Phase 3 Interventional Results available

Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients

NCT02555371

View directory record Official record

Conditions: Asthma
Interventions: Mepolizumab 100mg, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older

Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 13
States / cities: Long Beach, California • Riverside, California • Denver, Colorado + 10 more

Source: ClinicalTrials.gov public record

Updated Feb 4, 2020 · Synced May 22, 2026, 3:53 AM EDT

Completed Phase 3 Interventional Results available

Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04719832

View directory record Official record

Conditions: Asthma
Interventions: GSK3511294 (Depemokimab), Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older

Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 30
States / cities: Encinitas, California • Long Beach, California • Pasadena, California + 25 more

Source: ClinicalTrials.gov public record

Updated Dec 16, 2024 · Synced May 22, 2026, 3:53 AM EDT

Completed Phase 3 Interventional Results available

Study of Mepolizumab Autoinjector in Asthmatics

NCT03099096

View directory record Official record

Conditions: Asthma
Interventions: Mepolizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older

Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 16
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 13 more

Source: ClinicalTrials.gov public record

Updated Jun 27, 2023 · Synced May 22, 2026, 3:53 AM EDT

Completed Phase 2 Interventional Results available

Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma

NCT03469934

View directory record Official record

Conditions: Eosinophilic Asthma
Interventions: Etokimab, Placebo; Biological · Drug
Lead sponsor: AnaptysBio, Inc.; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Normal, Illinois • Novi, Michigan • Edmond, Oklahoma + 1 more

Source: ClinicalTrials.gov public record

Updated Aug 15, 2023 · Synced May 22, 2026, 3:53 AM EDT

Completed Phase 3 Interventional Results available

A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects

NCT02135692

View directory record Official record

Conditions: Asthma
Interventions: Mepolizumab, SOC; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older

Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 16
States / cities: Newport Beach, California • Riverside, California • Rolling Hills Estates, California + 13 more

Source: ClinicalTrials.gov public record

Updated Dec 2, 2019 · Synced May 22, 2026, 3:53 AM EDT

Active, not recruiting Phase 4 Interventional

REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study

NCT06041386

View directory record Official record

Conditions: Asthma
Interventions: Mepolizumab, Spirometry; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older

Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 28
States / cities: La Jolla, California • Newport Beach, California • Aurora, Colorado + 24 more

Source: ClinicalTrials.gov public record

Updated Jul 31, 2025 · Synced May 22, 2026, 3:53 AM EDT

Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma

NCT03299686

View directory record Official record

Conditions: Asthma
Interventions: CJM112, Placebo to CJM112; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 8
States / cities: Fullerton, California • Riverside, California • Denver, Colorado + 5 more

Source: ClinicalTrials.gov public record

Updated Oct 7, 2021 · Synced May 22, 2026, 3:53 AM EDT

Completed Phase 3 Interventional Results available

An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

NCT05243680

View directory record Official record

Conditions: Asthma
Interventions: GSK3511294 (Depemokimab); Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older

Enrollment: 641 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 29
States / cities: Mobile, Alabama • Lancaster, California • Colorado Springs, Colorado + 23 more

Source: ClinicalTrials.gov public record

Updated Jan 14, 2026 · Synced May 22, 2026, 3:53 AM EDT

Completed Phase 4 Interventional Results available

Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients

NCT02654145

View directory record Official record

Conditions: Asthma
Interventions: Mepolizumab 100mg SC, Albuterol/salbutamol MDIs, Omalizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older

Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 13
States / cities: Birmingham, Alabama • Riverside, California • Roseville, California + 10 more

Source: ClinicalTrials.gov public record

Updated Aug 18, 2019 · Synced May 22, 2026, 3:53 AM EDT